跳转至内容
Merck
CN
  • Cancer-associated mutations in human pyruvate kinase M2 impair enzyme activity.

Cancer-associated mutations in human pyruvate kinase M2 impair enzyme activity.

FEBS letters (2019-10-24)
Vivian M Liu, Andrea J Howell, Aaron M Hosios, Zhaoqi Li, William J Israelsen, Matthew G Vander Heiden
摘要

Mammalian pyruvate kinase catalyzes the final step of glycolysis, and its M2 isoform (PKM2) is widely expressed in proliferative tissues. Mutations in PKM2 are found in some human cancers; however, the effects of these mutations on enzyme activity and regulation are unknown. Here, we characterized five cancer-associated PKM2 mutations, occurring at various locations on the enzyme, with respect to substrate kinetics and activation by the allosteric activator fructose-1,6-bisphosphate (FBP). The mutants exhibit reduced maximal velocity, reduced substrate affinity, and/or altered activation by FBP. The kinetic parameters of five additional PKM2 mutants that have been used to study enzyme function or regulation also demonstrate the deleterious effects of mutations on PKM2 function. Our findings indicate that PKM2 is sensitive to many amino acid changes and support the hypothesis that decreased PKM2 activity is selected for in rapidly proliferating cells.

材料
产品编号
品牌
产品描述

Roche
不含EDTA的cOmplete Mini蛋白酶抑制剂混合物, Protease Inhibitor Cocktail Tablets provided in a glass vial, Tablets provided in a glass vial